Adalimumab Treatment in Biologically Naïve Crohn’s Disease : Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
المؤلفون المشاركون
Kamiya, Takeshi
Tanida, Satoshi
Katano, Takahito
Nishiwaki, Hirotaka
Kubota, Eiji
Ozeki, Keiji
Joh, Takashi
Mori, Yoshinori
Ebi, Masahide
Mizoshita, Tsutomu
Tsukamoto, Hironobu
Kataoka, Hiromi
المصدر
Gastroenterology Research and Practice
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-04-16
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Background.
Adalimumab (ADA) is effective for patients with Crohn’s disease (CD).
However, there have been few reports on ADA therapy with respect to its relationship with pathologic findings and drug efficacy in biologically naïve CD cases.
Methods.
Fifteen patients with active biologically naïve CD were treated with ADA.
We examined them clinically and pathologically with ectopic MUC5AC expression in the lesions before and after 12 and 52 weeks of ADA therapy, retrospectively.
Results.
Both mean CD activity index scores and serum C-reactive protein values were significantly lower after ADA therapy (P<0.001).
In the MUC5AC negative group, all cases exhibited clinical remission (CR) and endoscopic improvement at 52 weeks.
In MUC5AC positive groups, loss of MUC5AC expression was detected in cases having CR and endoscopic improvement at 52 weeks, while remnant ectopic MUC5AC expression was observed in those exhibiting no endoscopic improvement and flare up after 52 weeks.
Conclusions.
ADA leads to CR and endoscopic improvement in biologically naïve CD cases.
In addition, ectopic MUC5AC expression may be a predictive marker of flare up and endoscopic improvement in the intestines of CD patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Mizoshita, Tsutomu& Tanida, Satoshi& Tsukamoto, Hironobu& Ozeki, Keiji& Katano, Takahito& Nishiwaki, Hirotaka…[et al.]. 2014. Adalimumab Treatment in Biologically Naïve Crohn’s Disease : Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement. Gastroenterology Research and Practice،Vol. 2014, no. 2014, pp.1-8.
https://search.emarefa.net/detail/BIM-490622
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Mizoshita, Tsutomu…[et al.]. Adalimumab Treatment in Biologically Naïve Crohn’s Disease : Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement. Gastroenterology Research and Practice No. 2014 (2014), pp.1-8.
https://search.emarefa.net/detail/BIM-490622
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Mizoshita, Tsutomu& Tanida, Satoshi& Tsukamoto, Hironobu& Ozeki, Keiji& Katano, Takahito& Nishiwaki, Hirotaka…[et al.]. Adalimumab Treatment in Biologically Naïve Crohn’s Disease : Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement. Gastroenterology Research and Practice. 2014. Vol. 2014, no. 2014, pp.1-8.
https://search.emarefa.net/detail/BIM-490622
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-490622
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر